 Black Diamond Therapeutics NASDAQ:REYN was downgraded by analysts at ValuEngine from a hold rating to a sell rating in a note issued to investors on Friday, ValuEngine reports. A number of other equities analysts have also issued reports on REYN. JPMorgan Chase Co. increased their price objective on Black Diamond Therapeutics from 37.00 to ... 